Tags

Type your tag names separated by a space and hit enter

Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients.
J Intern Med. 2020 Aug 03 [Online ahead of print]JI

Abstract

Severely ill COVID-19 patients have a high risk of admission to the intensive-care unit (ICU) and requirement for mechanical ventilation (MV), with in-hospital mortality reported as 18-79% globally.1-4 . Among ICU patients in the United States (US), centers have reported 50% mortality.5,6 Tocilizumab, an IL-6 receptor (IL-6R) antagonist, is FDA approved for the management of CAR T-cell related Cytokine Release Syndrome (CRS) and may have utility in treatment of some COVID-19 patients. We describe the clinical characteristics and initial outcomes of a cohort of patients treated with tocilizumab at the Swedish Medical Center in Seattle, Washington.

Authors+Show Affiliations

Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.Divisions of Infectious Disease, Swedish Medical Center, Seattle, WA, USA.Divisions of Infectious Disease, Swedish Medical Center, Seattle, WA, USA.Divisions of Infectious Disease, Swedish Medical Center, Seattle, WA, USA.Divisions of Infectious Disease, Swedish Medical Center, Seattle, WA, USA.Hospital Medicine, Swedish Medical Center, Seattle, WA, USA.Pulmonary and Critical Care, Swedish Medical Center, Seattle, WA, USA.Pulmonary and Critical Care, Swedish Medical Center, Seattle, WA, USA.Pulmonary and Critical Care, Swedish Medical Center, Seattle, WA, USA.US Anesthesia Partners, Seattle, WA, USA. Swedish Heart and Vascular Institute, Swedish Medical Center, Seattle, WA, USA.Swedish Heart and Vascular Institute, Swedish Medical Center, Seattle, WA, USA.Swedish Heart and Vascular Institute, Swedish Medical Center, Seattle, WA, USA.Swedish Heart and Vascular Institute, Swedish Medical Center, Seattle, WA, USA.Divisions of Infectious Disease, Swedish Medical Center, Seattle, WA, USA.Center for Blood Disorders and Stem Cell Transplantation, Swedish Cancer Institute, Swedish Medical Center, Seattle, WA, USA.

Pub Type(s)

Letter

Language

eng

PubMed ID

32745348

Citation

Patel, Krish, et al. "Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients." Journal of Internal Medicine, 2020.
Patel K, Gooley TA, Bailey N, et al. Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients. J Intern Med. 2020.
Patel, K., Gooley, T. A., Bailey, N., Bailey, M., Hegerova, L., Batchelder, A., Holdread, H., Dunleavy, V., Downey, T., Frisvold, J., Megrath, S., Pagarigan, K., Szeto, J., Rueda, J., Islam, A., Maree, C., Nyatsatsang, S., Bork, S. E., Lipke, A., ... Pagel, J. M. (2020). Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients. Journal of Internal Medicine. https://doi.org/10.1111/joim.13163
Patel K, et al. Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients. J Intern Med. 2020 Aug 3; PubMed PMID: 32745348.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of the IL-6R Antagonist Tocilizumab in Hospitalized COVID-19 Patients. AU - Patel,Krish, AU - Gooley,Ted A, AU - Bailey,Neil, AU - Bailey,Megumi, AU - Hegerova,Livia, AU - Batchelder,Ami, AU - Holdread,Heather, AU - Dunleavy,Vanessa, AU - Downey,Tyler, AU - Frisvold,Jens, AU - Megrath,Samantha, AU - Pagarigan,Krystle, AU - Szeto,Jennie, AU - Rueda,Justin, AU - Islam,Adel, AU - Maree,Cynthia, AU - Nyatsatsang,Sonam, AU - Bork,Sarah E, AU - Lipke,Anne, AU - O'Mahony,D Shane, AU - Wagner,Teresa, AU - Pulido,Juan, AU - Mignone,John, AU - Youssef,Samuel, AU - Hartman,Matthew, AU - Goldman,Jason D, AU - Pagel,John M, Y1 - 2020/08/03/ PY - 2020/8/4/entrez PY - 2020/8/4/pubmed PY - 2020/8/4/medline KW - COVID-19 KW - Interleukin-6; cytokine KW - tocilizumab JF - Journal of internal medicine JO - J. Intern. Med. N2 - Severely ill COVID-19 patients have a high risk of admission to the intensive-care unit (ICU) and requirement for mechanical ventilation (MV), with in-hospital mortality reported as 18-79% globally.1-4 . Among ICU patients in the United States (US), centers have reported 50% mortality.5,6 Tocilizumab, an IL-6 receptor (IL-6R) antagonist, is FDA approved for the management of CAR T-cell related Cytokine Release Syndrome (CRS) and may have utility in treatment of some COVID-19 patients. We describe the clinical characteristics and initial outcomes of a cohort of patients treated with tocilizumab at the Swedish Medical Center in Seattle, Washington. SN - 1365-2796 UR - https://www.unboundmedicine.com/medline/citation/32745348/Use_of_the_IL-6R_Antagonist_Tocilizumab_in_Hospitalized_COVID-19_Patients L2 - https://doi.org/10.1111/joim.13163 DB - PRIME DP - Unbound Medicine ER -
Try the Free App:
Prime PubMed app for iOS iPhone iPad
Prime PubMed app for Android
Prime PubMed is provided
free to individuals by:
Unbound Medicine.